No More $35 Insulin Cap? Eli Lilly, Plaintiffs Call Off $13.5M Class Action Settlement

An unfavorable ruling by a judge has scuttled an agreement in which Eli Lilly would have capped insulin prices and paid $13.5 million to resolve claims that it had inflated the drug’s cost.

Lawyers for a proposed nationwide class of individuals, who paid for Lilly’s Humalog injection and other insulin drugs, said in a filing in Newark, N.J. federal court that they and Lilly had decided not to go forward seeking approval for the deal.

One lawyer, Steve Berman, told Reuters that the decision to drop the deal came after U.S. District Judge Brian Martinotti in February refused to certify a class in the litigation, which also targets insulin drug makers Novo Nordisk and Sanofi. The plaintiffs since have filed an amended version of their complaint, again seeking to proceed as a class action. Berman called the demise of the settlement, which would have capped patients’ out-of-pocket insulin costs at $35 per month for four years, a “potentially big loss for consumers.”

Lilly said in a statement that the plaintiffs’ claims lacked merit and that it would continue to defend itself. Lilly and the other companies still face lawsuits by several states, some of which objected to the settlement because it could interfere with their own litigation. The company in February settled with Minnesota, agreeing to cap prices and donate insulin to clinics in the state.

Plaintiffs in the cases allege that insulin manufacturers set artificially high list prices for their products, while paying rebates to pharmacy benefit managers in exchange for their covering the drug on behalf of health plans. Lilly said last March that it would slash insulin prices and make it available to many patients for $25 or $35, following pressure from the Biden administration, lawmakers and advocacy groups over skyrocketing costs.

A survey released last year by Sen. Elizabeth Warren, D-Mass., found that many patients nevertheless are still were being charged hundreds of dollars for treatments. Around 8.4 million of the 37 million people in the United States with diabetes use insulin, according to the American Diabetes Association.

 

Source Link

Recommended Articles

State PBM laws Face ERISA Preemption Challenges in Court

States seeking to limit the power of pharmacy benefit managers are running into legal roadblocks. Every state, as well as the federal government, has enacted PBM legislation over the last decade to rein in an industry accused of anticompetitive business practices. Those efforts have seen mixed results as agencies struggle to enforce requirements and courts ...

Read More

Employer Health Cost Crunch Is Worse Than Projected

There’s new evidence that double-digit health cost increases were hitting employers well before the forecasts of big spikes for 2027 — forcing big changes in workplace coverage for millions of Americans. Why it matters: The findings offer a higher-resolution view of how much health spending is putting a drag on the labor market and increasing ...

Read More

HHS Finalizes Changes To HIPAA Privacy Rule

HHS' Office for Civil Rights finalized a HIPAA privacy rule change cutting the protected health information request response window to 15 calendar days. The final regulation clarifies individuals can retrieve electronic PHI through health apps when entities can support that format.

Read More

Sutter Health-Allina Health Deal Clears Key Hurdle

Sutter Health and Allina Health have achieved a milestone in their plan to merge. The health systems agreed to invest $2.15 billion as part of a 10-year oversight arrangement that Minnesota Attorney General Keith Ellison (D) announced Monday. The deal has been under state review for months. Under terms of the agreement, Sacramento, California-based Sutter ...

Read More
arrowcaret-downclosefacebook-squarehamburgerinstagram-squarelinkedin-squarepauseplaytwitter-squareyoutube-square